

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8248517/sara-pilotto-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	2,232 citations	26 h-index	43 g-index
197 ext. papers	2,921 ext. citations	4 avg, IF	4.73 L-index

#	Paper	IF	Citations
144	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015 , 10, e0130142	3.7	339
143	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <i>Journal of Pathology</i> , 2017 , 241, 488-500	9.4	122
142	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	89
141	1701P Oncological patients' perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic. <i>Annals of Oncology</i> , 2020 , 31, S1003	10.3	78
140	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , 2018 , 10,	6.6	78
139	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	74
138	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020 , 130, 155-167	7.5	53
137	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , 2019 , 11,	6.6	47
136	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , 2014 , 17, 442-9	7.6	45
135	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1651-1661	8.9	44
134	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2015 , 6, 12783-95	3.3	44
133	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 472, 567-577	5.1	41
132	Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?. <i>Oncologist</i> , 2020 , 25, e555-e569	5.7	41
131	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015 , 5, 17499	4.9	40
130	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 30-6	8.7	39
129	ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 729-32	8.9	39
128	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016 , 5, 2-15	4.4	38

127	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016 , 21, 283-91	5.7	35
126	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1564-S1580	2.6	35
125	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020 , 21, 15-20	4.9	34
124	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , 2018 , 39, 971-980	4.6	32
123	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. <i>Annals of Translational Medicine</i> , 2017 , 5, 2	3.2	32
122	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104	4.9	31
121	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102858	7	28
120	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020 , 12,	6.6	27
119	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019 , 20, e186-e194	4.9	27
118	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 115	12.8	23
117	Prognostic impact of alternative splicing-derived hMENSA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , 2014 , 5, 11054-63	3.3	23
116	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 535-49	4.1	22
115	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015 , 4, 721-7	4.4	22
114	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2253-2266	4	22
113	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019 , 2019, 7652014	4.3	21
112	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 1055-1069	3.8	19
111	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 54-66	7	19
110	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019 , 11,	6.6	18

109	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1113-29	4	18
108	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017 , 60, 1-11	14.4	17
107	Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	16
106	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 847-56	14.4	15
105	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015 , 3, 265	3.2	15
104	Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 148, 102862	7	14
103	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. <i>Scientific Reports</i> , 2016 , 6, 22982	4.9	13
102	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1341-1348	8.9	13
101	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e105-6	8.9	13
100	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017 , 35, 21-26	3.6	12
99	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1359-70	5.4	11
98	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 50-9	7	11
97	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 135-45	7	11
96	Platelets and their role in cancer evolution and immune system. <i>Translational Lung Cancer Research</i> , 2015 , 4, 713-20	4.4	11
95	Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 141, 43-53	7	10
94	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5325-5334	3.1	10
93	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 937-945	5.4	10
92	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3958-72	3.3	10

91	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015 , 15, 307-13	2.2	10
90	Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. <i>Thrombosis Research</i> , 2020 , 194, 216-219	8.2	10
89	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020 , 21, 1-14.e3	4.9	10
88	Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. <i>European Journal of Cancer</i> , 2020 , 135, 159-169	7.5	9
87	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 568-575	8.9	9
86	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , 2016 , 17, 105	7.3	9
85	Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy. <i>PLoS ONE</i> , 2021 , 16, e0248714	3.7	8
84	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83	7.5	8
83	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , 2016 , 29, 24-30	3.6	8
82	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015 , 4, 704-12	4.4	7
81	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
80	Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	7
79	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. <i>Clinical Lung Cancer</i> , 2019 , 20, e514-e516	4.9	6
78	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019 , 105, 3-14	1.7	6
77	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 1381-97	6.2	6
76	PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 597-608	4	6
75	Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420971365	3	6
74	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 164, 103404	7	6

73	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1143-61	5.9	5
72	"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients. <i>PLoS ONE</i> , 2020 , 15, e0227846	3.7	5
71	Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015 , 15, 15-25	2.2	5
70	Other targeted drugs in melanoma. <i>Annals of Translational Medicine</i> , 2015 , 3, 266	3.2	5
69	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021 , 6, 100104	6	5
68	P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET). <i>Journal of Thoracic Oncology</i> , 2019 , 14, S644	8.9	5
67	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 921-930	3.8	5
66	Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 497-506	5.4	4
65	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S266-S267	8.9	4
64	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015 , 88, 319-24	5.9	4
63	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , 2020 , 5, e000689	6	4
62	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , 2020 , 10, 588862	5.3	4
61	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020 , 150, 123-131	5.9	4
60	Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa071	4.6	4
59	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , 2021 , 11, 650293	5.3	4
58	A multimodal approach to cancer-related cachexia: from theory to practice. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 819-826	3.5	4
57	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , 2021 , 11, 669786	5.3	4
56	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 50	12.8	4

55	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1583-1592	7.4	4
54	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. <i>Cancer Biomarkers</i> , 2017 , 18, 215-220	3.8	3
53	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020 , 50, 56-63	3.6	3
52	Clinical meta-analyses of targeted therapies in adenocarcinoma. <i>Targeted Oncology</i> , 2013 , 8, 35-45	5	3
51	Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. <i>Future Science OA</i> , 2020 , 7, FSO659	2.7	3
50	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , 2018 , 45, 176-180	5.5	3
49	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2574-2585	2.2	3
48	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1847-1855	3.6	3
47	Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. <i>Cancer Genetics</i> , 2017 , 210, 28-33	2.3	2
46	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 531-542	3.5	2
45	Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease. <i>Clinical Respiratory Journal</i> , 2018 , 12, 1150-1159	1.7	2
44	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. <i>Pulmonary Therapy</i> , 2016 , 2, 1-18	3	2
43	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. <i>ESMO Open</i> , 2021 , 7, 100308	6	2
42	A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3369-3384	4.4	2
41	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021 , 22, 351-360	4.9	2
40	Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. <i>Immunotherapy</i> , 2021 , 13, 971-976	3.8	2
39	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 688889	5.3	2
38	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 191-198	4.9	1

37	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 254-63	7	1
36	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019 , 134, 121-126	5.9	1
35	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16769-e16769	2.2	1
34	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020 , 22, 294-301	3.6	1
33	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103300	7	1
32	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , 2021 , 60, 6-14	3.6	1
31	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. <i>Nutrition</i> , 2022 , 98, 111637	4.8	1
30	Exercise oncology: It is time to make a change.. <i>Patient Education and Counseling</i> , 2022 ,	3.1	0
29	Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research. <i>European Journal of Oncology Nursing</i> , 2021 , 55, 102061	2.8	0
28	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103536	7	0
27	Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMA approval.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17555-e17555	2.2	0
26	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021 , 17, 2513-2527	3.6	0
25	Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability. <i>Journal of Cancer Education</i> , 2021 , 1	1.8	0
24	Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy?. <i>Acta Oncologica</i> , 2021 , 1-5	3.2	0
23	SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.. <i>Frontiers in Oncology</i> , 2022 , 12, 840783	5.3	0
22	Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-11	3.5	0
21	Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 175, 103726	7	0
20	Aberrations in NSCLC: So Close Yet So Far.. <i>JCO Precision Oncology</i> , 2020 , 4, 1049-1051	3.6	

19	Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. <i>EBioMedicine</i> , 2015 , 2, 782-3	8.8
18	Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. <i>Lung Cancer Management</i> , 2013 , 2, 89-92	2.6
17	EXPLORE EXERCISE LEVEL AND PREFERENCES IN PANCREATIC CANCER PATIENTS. <i>Medicine and Science in Sports and Exercise</i> , 2020 , 52, 485-486	1.2
16	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.. <i>Translational Cancer Research</i> , 2019 , 8, S16-S22	0.3
15	Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12056-12056	2.2
14	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9598-9598	2.2
13	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19059-e19059	2.2
12	Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 545-545	2.2
11	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 544-544	2.2
10	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 539-539	2.2
9	Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 630-630	2.2
8	Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 399-399	2.2
7	How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16053-e16053	2.2
6	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021 , 2, 207-222	0.4
5	Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 635-8	5.9
4	Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients 2020 , 15, e0227846	
3	Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients 2020 , 15, e0227846	
2	Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients 2020 , 15, e0227846	

- 1 Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients **2020**, 15, e0227846